title: Urinary eosinophil protein X and serum eosinophil cationic protein in infants and young children with atopic dermatitis: correlation with disease activity.
abstract: BACKGROUND
  Eosinophil cationic protein (ECP) and eosinophil protein X (EPX) or eosinophil-derived neurotoxin (EDN) are released by eosinophil granulocytes in allergic diseases. Serum ECP (s-ECP) levels have been correlated with disease activity in atopic dermatitis (AD) in adults and young patients, and high urinary EPX (u-EPX) levels in asthmatic patients seem to reflect active disease. A relationship between AD severity and u-EPX concentration in young children has not been previously studied.
  
  
  OBJECTIVE
  This study was performed to evaluate whether the severity of AD in infants and young children was correlated with s-ECP and u-EPX levels.
  
  
  METHODS
  Fifty-four infants and children (mean age, 17.7 months; range, 4-48 months) with AD and without other allergic conditions were evaluated. The severity of AD was measured by using the SCORAD index. S-ECP, serum total IgE, serum-specific IgE for common allergens, and peripheral blood eosinophil counts (PBECs) were determined. In forty-two children u-EPX was also measured. Seven age-matched control patients underwent the same determinations.
  
  
  RESULTS
  S-ECP and u-EPX were significantly higher in children with AD than in control children (mean, 23.9 vs 3.5 microg/dL [P <.001] and 57.7 vs 6.0 microg/mmol creatinine [P <.001]). A significant correlation was found between SCORAD and s-ECP (P =.002), u-EPX (P =.01), and PBECs (P =.01) and between symptom index and uEPX (P =.0004). PBECs were strongly correlated to s-ECP and u-EPX (P <.0001). However, 5 patients with moderate and severe AD (11.9%) showed low levels of s-ECP, u-EPX, and PBECs.
  
  
  CONCLUSIONS
  S-ECP and u-EPX were useful markers of AD activity in infants and young children. When taken together, the two determinations could give more information about the clinical course of the illness. Some patients seemed to have clinical exacerbations without an involvement of eosinophils and their products.
authors.affiliation: Allergy and Clinical Immunology Unit, Anna Meyer Hospital, Department of Pediatrics, University of Florence, Florence, Italy.
authors.forename: N
authors.initials: N
authors.lastname: Pucci
authors.forename: E
authors.initials: E
authors.lastname: Lombardi
authors.forename: E
authors.initials: E
authors.lastname: Novembre
authors.forename: S
authors.initials: S
authors.lastname: Farina
authors.forename: R
authors.initials: R
authors.lastname: Bernardini
authors.forename: E
authors.initials: E
authors.lastname: Rossi
authors.forename: T
authors.initials: T
authors.lastname: Favilli
authors.forename: A
authors.initials: A
authors.lastname: Vierucci
mesh_terms: D001798:Blood Proteins / Q000378:metabolism* / Q000652:urine*; D002675:Child, Preschool; D003876:Dermatitis, Atopic / Q000097:blood* / Q000276:immunology / Q000473:pathology / Q000652:urine*; D047091:Eosinophil Granule Proteins; D047208:Eosinophil-Derived Neurotoxin; D004804:Eosinophils / Q000378:metabolism*; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D007223:Infant; D007958:Leukocyte Count; D008297:Male; D012260:Ribonucleases; D012720:Severity of Illness Index
chemical_list: D001798:Blood Proteins; D047091:Eosinophil Granule Proteins; D007073:Immunoglobulin E; D047208:Eosinophil-Derived Neurotoxin; D012260:Ribonucleases